Based on a thorough and scientifically valid analysis of all relevant doubleblind randomized clinical trials (DBRCT), Neurontin is not an effective drug for thetreatment of neuropathic pain. My thorough review and meta-analysis of availablepublished…
BACKGROUND: There is good evidence of selective outcome reporting in published reports of randomized trials. METHODS: We examined reporting practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidiary, Parke-Davis (hereafter…